
TNFA Valuation
TNF Pharmaceuticals Inc
- Overview
- Forecast
- Valuation
- Earnings
TNFA Relative Valuation
TNFA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TNFA is overvalued; if below, it's undervalued.
Historical Valuation
TNF Pharmaceuticals Inc (TNFA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of TNF Pharmaceuticals Inc (TNFA) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price:0.10
Fair
0.00
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
TNF Pharmaceuticals Inc. (TNFA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
0.00
EV/EBIT
TNF Pharmaceuticals Inc. (TNFA) has a current EV/EBIT of 0.00. The 5-year average EV/EBIT is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBIT of 0.00 falls within the Strongly Undervalued range.
0.00
PS
TNF Pharmaceuticals Inc. (TNFA) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
0.00
P/OCF
TNF Pharmaceuticals Inc. (TNFA) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.00
P/FCF
TNF Pharmaceuticals Inc. (TNFA) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
TNF Pharmaceuticals Inc (TNFA) has a current Price-to-Book (P/B) ratio of 0.09. Compared to its 3-year average P/B ratio of -7.98 , the current P/B ratio is approximately -101.07% higher. Relative to its 5-year average P/B ratio of -5.11, the current P/B ratio is about -101.67% higher. TNF Pharmaceuticals Inc (TNFA) has a Forward Free Cash Flow (FCF) yield of approximately -665.17%. Compared to its 3-year average FCF yield of -212.16%, the current FCF yield is approximately 213.53% lower. Relative to its 5-year average FCF yield of -150.27% , the current FCF yield is about 342.66% lower.
0.09
P/B
Median3y
-7.98
Median5y
-5.11
-665.17
FCF Yield
Median3y
-212.16
Median5y
-150.27
Competitors Valuation Multiple
The average P/S ratio for TNFA's competitors is 0.00, providing a benchmark for relative valuation. TNF Pharmaceuticals Inc Corp (TNFA) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TNFA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of TNFA in the past 1 year is driven by Unknown.
People Also Watch

AQB
AquaBounty Technologies Inc
0.748
USD
+1.22%

SHPH
Shuttle Pharmaceuticals Holdings Inc
3.420
USD
-2.84%

PTIX
Protagenic Therapeutics Inc
2.830
USD
+0.35%

YCBD
cbdMD Inc
0.883
USD
+6.39%

KTTA
Pasithea Therapeutics Corp
0.682
USD
-2.57%

AZTR
Azitra Inc
0.164
USD
-2.38%

TC
Token Cat Ltd
0.600
USD
-3.23%

CNET
ZW Data Action Technologies Inc
1.317
USD
+1.31%

ICON
Icon Energy Corp
2.270
USD
-1.30%
FAQ

Is TNF Pharmaceuticals Inc (TNFA) currently overvalued or undervalued?
TNF Pharmaceuticals Inc (TNFA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of TNF Pharmaceuticals Inc (TNFA) is between to according to relative valuation methord.

What is TNF Pharmaceuticals Inc (TNFA) fair value?

How does TNFA's valuation metrics compare to the industry average?

What is the current P/B ratio for TNF Pharmaceuticals Inc (TNFA) as of Aug 09 2025?

What is the current FCF Yield for TNF Pharmaceuticals Inc (TNFA) as of Aug 09 2025?

What is the current Forward P/E ratio for TNF Pharmaceuticals Inc (TNFA) as of Aug 09 2025?
